drugset / Trial / NCT05042076
BK With VST for Kidney Transplant Patients
NaSingle-groupOpen-labelTreatment
Summary
This study measures the safety, feasibility, and efficacy of viral-specific T cells (VST) against BK Virus (BKV) in adult kidney transplant recipients. Participants are expected to be on study for 52 weeks.
Timeline
- Start
- 2021-12-16
- Primary completion
- 2024-05-14
- Completion
- 2024-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BK-specific T cells from Donor Lymphocytes | Cell therapy | 300 cells/kg | Intravenous |
| Subject | BK-specific T cells from Donor Lymphocytes | Cell therapy | 5000 cells/kg | Intravenous |